April 2011
Volume 52, Issue 14
Free
ARVO Annual Meeting Abstract  |   April 2011
The Nitric Oxide (no)-donating Triamcinolone Acetonide, NCX 434, Does Not Increase Intraocular Pressure and Reduces Endothelin-1-induced Biochemical and Functional Changes In The Rabbit Eye
Francesco Impagnatiello; Barbara Giambene; Cecilia Lanzi; Alessandro Pini; Teresa Somma; Elena Bastia; Ennio Ongini; Ugo Menchini; Fernando Galassi; Emanuela Masini
Author Affiliations & Notes
  • Francesco Impagnatiello
    Nicox Research Institute, Bresso (Milan), Italy
  • Barbara Giambene
    Eye Clinic University of Florence, Florence, Italy
  • Cecilia Lanzi
    Department of Preclinical and Clinical Pharmacology,
    University of Florence, Florence, Italy
  • Alessandro Pini
    Department of Anatomy, Histology and Forensic Medicine,
    University of Florence, Florence, Italy
  • Teresa Somma
    Department of Preclinical and Clinical Pharmacology,
    University of Florence, Florence, Italy
  • Elena Bastia
    Nicox Research Institute, Bresso (Milan), Italy
  • Ennio Ongini
    Nicox Research Institute, Bresso (Milan), Italy
  • Ugo Menchini
    Eye Clinic University of Florence, Florence, Italy
  • Fernando Galassi
    Eye Clinic University of Florence, Florence, Italy
  • Emanuela Masini
    Department of Preclinical and Clinical Pharmacology,
    University of Florence, Florence, Italy
  • Footnotes
    Commercial Relationships  Francesco Impagnatiello, Nicox Research Institute (E); Barbara Giambene, None; Cecilia Lanzi, None; Alessandro Pini, None; Teresa Somma, None; Elena Bastia, Nicox Research Institute (E); Ennio Ongini, Nicox Research Institute (E); Ugo Menchini, None; Fernando Galassi, None; Emanuela Masini, None
  • Footnotes
    Support  None
Investigative Ophthalmology & Visual Science April 2011, Vol.52, 6065. doi:
  • Views
  • Share
  • Tools
    • Alerts
      User Alerts
      You are adding an alert for:
      The Nitric Oxide (no)-donating Triamcinolone Acetonide, NCX 434, Does Not Increase Intraocular Pressure and Reduces Endothelin-1-induced Biochemical and Functional Changes In The Rabbit Eye
      You will receive an email whenever this article is corrected, updated, or cited in the literature. You can manage this and all other alerts in My Account
      The alert will be sent to:
      ×
      This feature is available to authenticated users only.
      Sign In or Create an Account ×
    • Get Citation
      Citation

      Francesco Impagnatiello, Barbara Giambene, Cecilia Lanzi, Alessandro Pini, Teresa Somma, Elena Bastia, Ennio Ongini, Ugo Menchini, Fernando Galassi, Emanuela Masini; The Nitric Oxide (no)-donating Triamcinolone Acetonide, NCX 434, Does Not Increase Intraocular Pressure and Reduces Endothelin-1-induced Biochemical and Functional Changes In The Rabbit Eye. Invest. Ophthalmol. Vis. Sci. 2011;52(14):6065.

      Download citation file:

      © ARVO (1962-2015); The Authors (2016-present)

      ×
    • Get Permissions
  • Supplements
Abstract

Purpose: : NCX 434 is a novel nitric oxide (NO)-donating triamcinolone acetonide (TA) with low liability to increase intraocular pressure (IOP). It also demonstrated to enhance oxygen saturation in non-human primate optic nerve head (ONH). We compared the effects of intravitreal (IVT) administration of NCX 434 and TA at equimolar doses on IOP, retinal function and retrobulbar haemodymamics in the endothelin-1 (ET-1)-induced ONH ischemia/reperfusion rabbit model. Biochemical changes were also assessed in aqueous humour and in retinal biopsies.

Methods: : IOP and resistivity index of ophthalmic artery (RI-OA) were recorded by means of TonoPen and ecocolorDoppler, respectively. Retinal function was assessed using photopic electroretinography (ERG). Cytokine expression and oxidative stress markers were evaluated with immunoassay techniques.

Results: : ET-1 did not change IOP and RI-OA, but decreased photopic ERG amplitude over time. TA increased IOP while NCX 434 did not (Vehicle= 13.6±1.3, NCX 434= 16.9±2.2, TA= 20.9±1.9 mmHg*, p<0.05 vs. vehicle) 4-week post IVT treatment. RI-OA was higher following TA than after NCX 434 (Vehicle= 0.44±0.03; NCX 434= 0.47±0.02; TA= 0.60±0.04 *, p<0.05 vs. vehicle) 4-week post IVT treatment. Both NCX 434 and TA reversed ERG amplitude decrease (Vehicle=62.1±6.7; NCX 434= 149.7±7.2*; TA=131.4±9.1 uV*, p<0.05 vs. vehicle). NCX 434 also reduced oxidative stress markers, caspase-3 activity and nitrotyrosine formation in retinal tissue as well as IL6 and TNFα in aqueous humor more effectively than TA.

Conclusions: : The IVT administration of NCX 434 attenuates the effects of ischemia/reperfusion damage to ONH and retina without increasing IOP. This compound is an interesting new development opportunity for the treatment of retinal and ONH diseases.

Keywords: ischemia • diabetic retinopathy • vascular occlusion/vascular occlusive disease 
© 2011, The Association for Research in Vision and Ophthalmology, Inc., all rights reserved. Permission to republish any abstract or part of an abstract in any form must be obtained in writing from the ARVO Office prior to publication.
Copyright © 2025 Association for Research in Vision and Ophthalmology.
×
×

This PDF is available to Subscribers Only

Sign in or purchase a subscription to access this content. ×

You must be signed into an individual account to use this feature.

×
This site uses cookies. By continuing to use our website, you are agreeing to our privacy policy.Accept